Psilocybin
Bia Labate of the Chacruna Institute: Truffle Talks Episode 14
James sits down with Dr. Bia Labate to discuss the many projects of the Chacruna Institute. Dr. Beatriz Caiuby Labate (Bia Labate) is a queer Brazilian…
James sits down with Dr. Bia Labate to discuss the many projects of the Chacruna Institute.
Dr. Beatriz Caiuby Labate (Bia Labate) is a queer Brazilian anthropologist based in San Francisco.
She has a Ph.D. in social anthropology from the State University of Campinas (UNICAMP), Brazil. Her main areas of interest are the study of plant medicines, drug policy, shamanism, ritual, religion, and social justice.
She is Executive Director of the Chacruna Institute for Psychedelic Plant Medicines. She serves as Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS), and Adjunct Faculty at the East-West Psychology Program at the California Institute of Integral Studies (CIIS).
She is also a member of the Oregon Psilocybin Advisory Board’s Research Subcommittee, and Diversity, Culture, and Ethics Advisor at the Synthesis Institute. Additionally, she is a co-founder of the Interdisciplinary Group for Psychoactive Studies (NEIP) in Brazil and editor of its site. She is author, co-author, and co-editor of twenty-four books, two special-edition journals, and several peer-reviewed articles.
The post Bia Labate of the Chacruna Institute: Truffle Talks Episode 14 appeared first on Truffle Report.
psilocybin psychedelic psychoactive synthesis research-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation7 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights